Luye Pharma (HKG:2186) said it enrolled the first patient in a Phase 2 clinical trial in China for its investigational drug LY03017, according to a Wednesday Hong Kong bourse filing.
Shares of the pharma company fell over 2% in late-morning trade Thursday.
The drug is being tested for the treatment of psychosis associated with Alzheimer's disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.